Compare MSGM & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | GTBP |
|---|---|---|
| Founded | 2018 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.1M |
| IPO Year | 2020 | 2016 |
| Metric | MSGM | GTBP |
|---|---|---|
| Price | $4.48 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 149.6K | ★ 736.5K |
| Earning Date | 06-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | 3.75 |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $741,000.00 | N/A |
| Revenue This Year | $69.07 | N/A |
| Revenue Next Year | $30.56 | N/A |
| P/E Ratio | $3.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.39 |
| 52 Week High | $5.78 | $3.73 |
| Indicator | MSGM | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 37.17 |
| Support Level | $2.59 | $0.41 |
| Resistance Level | $4.57 | $0.59 |
| Average True Range (ATR) | 0.53 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 44.12 | 35.43 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.